HC Wainwright Reaffirms “Buy” Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

HC Wainwright reiterated their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research note released on Monday,Benzinga reports. They currently have a $20.00 price objective on the stock.

Checkpoint Therapeutics Stock Performance

Shares of CKPT stock opened at $3.39 on Monday. The stock’s fifty day moving average price is $3.50 and its two-hundred day moving average price is $2.67. Checkpoint Therapeutics has a fifty-two week low of $1.36 and a fifty-two week high of $4.50. The company has a market cap of $165.53 million, a PE ratio of -1.84 and a beta of 1.34.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.08). On average, equities analysts predict that Checkpoint Therapeutics will post -0.91 EPS for the current fiscal year.

Institutional Investors Weigh In On Checkpoint Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in shares of Checkpoint Therapeutics by 67.4% during the 1st quarter. Vanguard Group Inc. now owns 917,894 shares of the company’s stock worth $1,882,000 after buying an additional 369,586 shares in the last quarter. Choreo LLC raised its holdings in shares of Checkpoint Therapeutics by 12.2% in the 2nd quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after acquiring an additional 7,080 shares in the last quarter. XTX Topco Ltd purchased a new stake in Checkpoint Therapeutics during the second quarter valued at about $34,000. B. Riley Wealth Advisors Inc. grew its holdings in shares of Checkpoint Therapeutics by 366.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock valued at $493,000 after purchasing an additional 180,050 shares during the last quarter. Finally, PVG Asset Management Corp purchased a new stake in shares of Checkpoint Therapeutics during the second quarter valued at approximately $295,000. 22.00% of the stock is owned by institutional investors.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.